Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 151

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 151
---
    Statements of Cash Flows for the years ended December 31, 2024 and 2023
    F-6

    Notes to the Financial Statements
    F-7

(2)Financial Statement Schedules:

All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.

(3)Exhibits:

The list of exhibits filed with this Annual Report on Form 10-K is set forth in the Exhibit Index preceding the signature page and is incorporated herein by reference or filed with this Annual Report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K). 

Item 16. Form 10-K Summary.

None.

90

Exhibit Index

    Incorporated by Reference

    ExhibitNumber
     
    Description
     
    Form
     
    File No.
     
    Exhibit
     
    Filing Date

    3.1
     
    ﻿Amended and Restated Certificate of Incorporation.
     
    8-K
     
    001-41331
     
    3.1
     
    June 24 2025

    3.2
     
    ﻿Amended and Restated Bylaws.
     
    S-1
     
    333-263295
     
    3.4
     
    March 4, 2022

    3.3
     
    Certificate of Designations of Series A Junior Participating Preferred Stock of AN2 Therapeutics, Inc. filed with the Secretary of State of the State of Delaware on August 15, 2024.
     
    8-K
     
    001-41331
     
    3.1
     
    August 19, 2024

    4.1
     
    Form of Common Stock Certificate.
     
    S-1
     
    333-263295
     
    4.1
     
    March 21, 2022

    4.2
     
    Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated March 5, 2021.
     
    S-1
     
    333-263295
     
    4.2
     
    March 4, 2022

    4.3
     
    Description of Securities
     
    10-K